Brepocitinib tosylate by Priovant Therapeutics for Hidradenitis Suppurativa: Likelihood of Approval
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Brepocitinib tosylate overview
Brepocitinib tosylate is under development for the treatment of moderate to severe hidradenitis suppurativa, systemic lupus erythematosus, dermatomyositis, non-infectious uveitis, posterior uveitis, panuveitis, intermediate uveitis. It is administered through the oral route as a tablet and by topical route as cream. It acts by targeting both JAK1 and TYK2 protein kinases.
It was also under development for the treatment of plaque psoriasis, mild to moderate atopic dermatitis (AD), Crohn’s disease, psoriatic arthritis, cicatricial alopecia (CA), psoriasis, active non-segmental vitiligo and moderate to severe ulcerative colitis.
Access the most comprehensive Company Profiles
on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Company Profile – free
sample
Thank you!
Your download email will arrive shortly
We are confident about the
unique
quality of our Company Profiles. However, we want you to make the most
beneficial
decision for your business, so we offer a free sample that you can download by
submitting the below form
By GlobalData
Priovant Therapeutics overview
Priovant Therapeutics is dedicated to developing and commercializing novel therapies for autoimmune diseases. Priovant Therapeutics is headquartered in New York City, New York, the US.
For a complete picture of Brepocitinib tosylate’s drug-specific PTSR and LoA scores, buy the report here.
Source link
#Brepocitinib #tosylate #Priovant #Therapeutics #Hidradenitis #Suppurativa #Likelihood #Approval
